Roche's Molecular Dx, Applied Science Revenues Rise in First-Half '09

Roche's MDx sales grew 5 percent in the first half of 2009, driven by its blood-screening portfolio and the recent launch of its TheraScreen K-RAS Mutation Test.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.